Back to Journals » Neurobehavioral HIV Medicine » Volume 2

Impact of HIV infection and alcohol on cognition: a review

Authors Ola A Selnes

Published 20 October 2010 Volume 2010:2 Pages 85—94

DOI https://doi.org/10.2147/NBHIV.S7364

Review by Single-blind

Peer reviewer comments 2

Ola A Selnes
Department of Neurology, Division of Cognitive Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract: Both alcohol and HIV (human immunodeficiency virus) can affect the structure and function of the central nervous system. What they have in common is that the white matter of the brain is principally affected, and the direct neuronal injury does not appear to be a consequence of either HIV infection or alcohol use. There is evidence that the cognitive effects of both HIV and alcohol are potentially reversible with treatment or abstinence. There is only limited overlap in terms of the actual brain regions or structures affected, which may account for the observation that the combined effects of alcohol and HIV are largely additive. Although the incidence of alcohol-related Korsakoff amnesia has declined, alcohol use nonetheless is associated with decreased cognitive performance. In the context of HIV infection, very heavy alcohol use in individuals with advanced HIV disease appears to have synergistic effects. Because current studies on the combined effects of alcohol and HIV infection are limited by several issues, including the use of relatively small sample sizes and nonuniform definitions of what constitutes heavy alcohol use, our understanding of the neurological and behavioral complications of this problem still remains incomplete.

Keywords: central nervous system, alcohol, cognition, HIV, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Anti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review

Imashuku S, Hasegawa T, Kubo K, Nakato M, Shima M

International Medical Case Reports Journal 2011, 4:31-34

Published Date: 20 April 2011

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010